Brief: Radiopharm Gets DSMC Nod To Accelerate Phase 1 Dose Escalation Trial Of 177Lu-RAD202
01/10/2025 14:43
Oct 1 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY AND MONITORING COMMITTEE (DSMC) TO ACCELERATE 177LU-RAD202 PHASE 1 ‘HEAT’ DOSE ESCALATION CLINICAL TRIAL Source text: ID:nGNX5hr6nY Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%